Kirk Nielsen is a Minneapolis-based Managing Partner at Vensana Capital, a medtech-focused venture capital and growth equity firm launched with the support of Versant. At Versant, Kirk led or co-led investments into Cameron Health (sale), CardiAQ (sale), Ceterix Orthopaedics (sale), Lutonix (sale), NeuWave Medical (sale), Sequent Medical (sale), Zyga Technology (sale), Inari Medical, Metavention, Monteris Medical, Nuvaira, Respicardia, and Veran Medical.
Kirk joined Versant in 2006 from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division. Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. Kirk earned his AB from Harvard College and his MBA from Harvard Business School.